Increasingly common independent medicine production to offset high prices in the United States

Increasingly common independent medicine production to offset high prices in the United States

There is a growing initiative to produce medicines by groups of hospitals, startups and non-profit organizations, in order to compete with the high prices of drugs in the United States.

Americans have little competition in the production of drugs, which is why their prices are so high.

Given the inaction of Washington and the shortage of some drugs, the idea of ​​independent drugs arises. Some initiatives are already distributed in millions of doses throughout the country.

What’s more, Already almost half of US hospitals can offer drugs that come from these independent projects, most so-called generic drugs.

Others are trying to produce new drugs and the idea is that the cost is always lower than that of the competition.

In this regard, Stacie Dusetzina, professor of public health at Vanderbilt University in Nashville, says that Despite these companies tackling the problem and trying novel solutions, it is not known to what extent there is a benefit to people.

Therefore, for Dusetzina “People should have access to the medicines they need without going bankrupt.” The good news is that this type of project generates competition, at least in certain medicines.

In the same way, Dr. Aaron Kesselheim, a researcher at Harvard Medical School and an expert on prices, thinks: “Without a doubt, these projects will cause some medicines to fall in price.”

One example is Civica Rx, launched in several hospitals three years ago and now supplying some 50 injectable drugs to more than 1,400 hospitals, and to the departments of Defense and Veterans Affairs. Even hospitalized patients have been treated with CONID-19.

And now they are requesting to sell directly to the consumer. CivicaScript will start with some generic drugs, a little more expensive. They will be sold by 2023 to some 50,000 pharmacies.

So did the retail giant Walmart, which launched a low-cost insulin on the market in late June through its private label ReliOn. According to the store, users will save up to 75% if we compare it with the same product but from other brands.

The new insulin is called NovoLog, a product worked directly with the manufacturer Novo Nordisk. Walmart assured that the low price does not compromise the quality of the product at all. NovoLog, are analog insulin vials and are sold at a price of $ 72.88 dollars and a Flexpen with a cost of $ 85.88 dollars.

With this type of Walmart store project, the consumer saves between $ 100 to $ 251.

And like these many projects, businessman Mark Cuban also wants to produce cheap alternative medicines without the need for health insurance. That project is scheduled for this year with Cost Plus Drug Co.

For the production of these alternative medicines, they contract national factories and the ingredients are also national or European. The supply chain can be expanded with China and India but these countries limited their exports with the pandemic.


Source link